KHK 4083

Drug Profile

KHK 4083

Alternative Names: KHK4083

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Atopic dermatitis
  • No development reported Autoimmune disorders

Most Recent Events

  • 10 Apr 2017 Phase-I clinical trials in Atopic dermatitis in Japan (IV) (NCT03096223)
  • 27 Mar 2017 Kyowa Hakko Kirin Pharma plans a phase I trial for Atopic dermatitis in Japan (JapicCTI173543)
  • 01 Dec 2016 Phase-I clinical trials in Ulcerative colitis in Japan (IV) (NCT02985593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top